CEFQUINOME NORBROOK LC, 75 MG INTRAMAMMARY OINTMENT FOR LACTATING COWS

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

CEFQUINOME (AS SULFATE)

Mevcut itibaren:

Norbrook Laboratories Limited

ATC kodu:

QJ51DE90

INN (International Adı):

CEFQUINOME (AS SULFATE)

Doz:

75 mg/syringe

Farmasötik formu:

intramammary Ointment

Reçete türü:

POM

Terapötik grubu:

Bovine

Terapötik alanı:

Cefquinome

Terapötik endikasyonlar:

Antibacterial

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2014-09-12

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cefquinome Norbrook LC, 75 mg Intramammary Ointment for Lactating Cows
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each pre-filled syringe of 8 g contains:
ACTIVE SUBSTANCE:
Cefquinome
75 mg
(as Cefquinome Sulfate)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Intramammary ointment.
A homogeneous off-white oily ointment.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (Lactating cow).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of clinical mastitis in the lactating cow caused by bacteria susceptible to cefquinome, namely
_Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, Escherichia coli_.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to cephalosporin antibiotics or other -lactam antibiotics, or to any of the
excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 12/09/2014_
_CRN 7015541_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
The product should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to
respond poorly, to other classes of antimicrobials or narrow spectrum -lactam antimicrobials.
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If it is not
possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the
target bacteria.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Use of the product deviating�